| Profiles RNS

Profile

MD, University of Pennsylvania School of Medicine

Websites

Research
Publications

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-Boosted Atazanavir Versus Ritonavir-Boosted Atazanavir Each Administered with Emtricitabine / Tenofovir Di
08/16/2010 - 08/15/2014 (PI)
Gilead Sciences, Inc.

A Phase IIB, Randomized, Multicenter, Parallel Group Study to Evaluate the Short-Term Safety, Pharmacokinetics and Antiviral Activity of Four Blinded Dosing Regimens of GW640385/Ritonavir Therapy
12/16/2005 - 12/15/2011 (PI)
GlaxoSmithKline LLC

A Multicenter, Randomized, Double-Blinde, Comparative Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination with Zidovudine/Lamivudine Versus EFA Virenz in Combination with Zidovudine/Lami
04/15/2005 - 04/14/2006 (PI)
Pfizer, Inc.

Std Preventive Clinical Services
07/01/2006 - 12/31/2015 (PI)
DPH DHHS

Enhanced Medical Management System Supplemental Services
07/01/2005 - 12/31/2015 (PI)
DPH

Harvard/Partners/BMC AIDS Clinical Trials Unit
12/01/2006 - 11/30/2014 (PI)
Mass General Hosp NIH-NIAID
5U01 AI069472-04

Implementing Computerized Clinical Assessment of HIV Patients Adherence
09/17/2007 - 07/31/2013 (PI)
Trustees of Boston University NIH
5R01 MH076911-02

Retaining HIV Positive Patients in Medical Care
10/01/2007 - 07/26/2013 (PI)
CDC

Ryan White Care Act Title IV - LHI Subcontract
09/01/2007 - 08/31/2012 (PI)
Latino Health Institute HRSA
H12HA23060-08

Comprehensive Home Based Medical Care Program
07/01/2005 - 06/30/2012 (PI)
DPH HRSA

HIV Counseling, Testing, and Support Services
07/01/2003 - 07/31/2011 (PI)
DPH CDC

HIV/AIDS Enhanced Medical Management Services (EMMS)
07/01/2005 - 06/30/2011 (PI)
DPH HRSA

AIDS Prevention and Education for Haitians in Boston
01/01/2007 - 06/30/2010 (PI)
DPH

Showing 10 of 30 results. Show All Results

Title

Yr	Title	Project-Sub Proj	Pubs
2010	BU Clinical HIV/AIDS Research Training Program	2T32AI052074-06A2	51
2009	PS04-064, HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION PROJECTS FOR CBO's	3U65PS123866-05S1
2008	PS04-064, HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION PROJECTS FOR CBO's	5U65PS123866-05
2007	HIV INFECTED SUBJECTS COMPARING TENOFOVIR DISOPROXIL FUMARATE AND EMTRICITABINE	2M01RR000533-39-8185	503
2007	PS04-064, HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION PROJECTS FOR CBO's	5U65PS123866-04
2006	INITIAL THERAPY FOR HIV-I INFECTION (ACTG A5142)	5M01RR000533-38-5585	503
2006	HIV INFECTED SUBJECTS COMPARING TENOFOVIR DISOPROXIL FUMARATE AND EMTRICITABINE	5M01RR000533-38-5627	503
2006	SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACOKINETICS IN HIV-1 INF MEN &WOMEN	5M01RR000533-38-5623	503
2006	HUMAN IMMUNODEFICIENCY VIRUS(HIV)PREVENTION PROJECTS FOR CBO	5U65PS123866-03
2006	Modeling of Lung HIV Cytokine/Chemokine Networks	5R01HL076114-04	32

Showing 10 of 67 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Wilson IB, Laws MB, Safren SA, Lee Y, Lu M, Coady W, Skolnik PR, Rogers WH. Provider-focused intervention increases adherence-related dialogue but does not improve antiretroviral therapy adherence in persons with HIV. J Acquir Immune Defic Syndr. 2010 Mar; 53(3):338-47. PMID: 20048680; PMCID: PMC2832106; DOI: 10.1097/QAI.0b013e3181c7a245;

Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010 Jun; 105(6):1231-8.View Related Profiles.

Farraye, Francis
Skolnik, Paul
Wasan, Sharmeel

PMID: 20104218; DOI: 10.1038/ajg.2009.733;

Su Z, Gulick RM, Krambrink A, Coakley E, Hughes MD, Han D, Flexner C, Wilkin TJ, Skolnik PR, Greaves WL, Kuritzkes DR, Reeves JD. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis. 2009 Dec 1; 200(11):1724-8. PMID: 19874179; PMCID: PMC2783913; DOI: 10.1086/648090;

Hosoya N, Su Z, Wilkin T, Gulick RM, Flexner C, Hughes MD, Skolnik PR, Giguel F, Greaves WL, Coakley E, Kuritzkes DR. Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions. J Clin Microbiol. 2009 Aug; 47(8):2604-6. PMID: 19494074; PMCID: PMC2725648; DOI: 10.1128/JCM.00632-09;

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Contact for Mentoring:

Yr	Title	Project-Sub Proj	Pubs
2010	BU Clinical HIV/AIDS Research Training Program	2T32AI052074-06A2	51
2009	PS04-064, HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION PROJECTS FOR CBO's	3U65PS123866-05S1
2008	PS04-064, HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION PROJECTS FOR CBO's	5U65PS123866-05
2007	HIV INFECTED SUBJECTS COMPARING TENOFOVIR DISOPROXIL FUMARATE AND EMTRICITABINE	2M01RR000533-39-8185	503
2007	PS04-064, HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION PROJECTS FOR CBO's	5U65PS123866-04
2006	INITIAL THERAPY FOR HIV-I INFECTION (ACTG A5142)	5M01RR000533-38-5585	503
2006	HIV INFECTED SUBJECTS COMPARING TENOFOVIR DISOPROXIL FUMARATE AND EMTRICITABINE	5M01RR000533-38-5627	503
2006	SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACOKINETICS IN HIV-1 INF MEN &WOMEN	5M01RR000533-38-5623	503
2006	HUMAN IMMUNODEFICIENCY VIRUS(HIV)PREVENTION PROJECTS FOR CBO	5U65PS123866-03
2006	Modeling of Lung HIV Cytokine/Chemokine Networks	5R01HL076114-04	32
2006	Training Program in Host Pathogen Interactions	5T32AI052070-05	17
2005	HUMAN IMMUNODEFICIENCY VIRUS(HIV)PREVENTION PROJECTS FOR CBO	5U65PS123866-02
2005	Modeling of Lung HIV Cytokine/Chemokine Networks	5R01HL076114-03	32
2005	Modeling of Lung HIV Cytokine/Chemokine Networks	3R01HL076114-03S1	32
2005	Training Program in Host Pathogen Interactions	5T32AI052070-04	17
2004	HUMAN IMMUNODEFICIENCY VIRUS(HIV)PREVENTION PROJECTS FOR CBO	5U65PS123866-01
2004	Modeling of Lung HIV Cytokine/Chemokine Networks	5R01HL076114-02	32
2004	Innate Immunity, HIV, and OIs: Role of TLRs in the Lung	5R21AI055374-02	1
2004	Training Program in Host Pathogen Interactions	5T32AI052070-03	17
2003	Modeling of Lung HIV Cytokine/Chemokine Networks	1R01HL076114-01	32
2003	Innate Immunity, HIV, and OIs: Role of TLRs in the Lung	1R21AI055374-01	1
2002	Lung TACE, TNFalpha &TNFR Regulation of HIV Replication	1R21AI051682-01A1
2002	ORALLY ADMINISTERED SP 303 FOR TREATMENT OF DIARRHEA IN AIDS PATIENTS	5M01RR000054-41-656	491
2002	CYTOKINES AND CYTOMEGALOVIRUS IN AIDS RELATED LUNG DISEASE	5M01RR000054-41-657	491
2002	Failing HAART--Do nutritional &clinical benefits persist	5M01RR000054-41-682	491
2001	CORE--IMMUNOVIROLOGY	5P30AI042853-04-9002	905
2001	CORE--IMMUNOVIROLOGY	3P30AI042853-04S1-9002	905
2001	CYTOKINES AND CYTOMEGALOVIRUS IN AIDS RELATED LUNG DISEASE	3M01RR000054-39S3-657	491
2001	ORALLY ADMINISTERED SP 303 FOR TREATMENT OF DIARRHEA IN AIDS PATIENTS	3M01RR000054-39S3-656	491
2001	Failing HAART--Do nutritional &clinical benefits persist	3M01RR000054-39S3-682	491
2001	NEMCH CLINICAL RESEARCH ON AIDS TRAINING GRANT	5T32AI007438-09	41
2001	HIV Pathogenesis Training Program	2T32AI007389-11	52
2000	CORE--IMMUNOVIROLOGY	5P30AI042853-03-9002	905
2000	ORALLY ADMINISTERED SP 303 FOR TREATMENT OF DIARRHEA IN AIDS PATIENTS	5M01RR000054-39-656	491
2000	CYTOKINES AND CYTOMEGALOVIRUS IN AIDS RELATED LUNG DISEASE	5M01RR000054-39-657	491
2000	CYTOKINES AND CMV IN AIDS RELATED LUNG DISEASE	5R01HL057875-05	2
2000	NEMCH CLINICAL RESEARCH ON AIDS TRAINING GRANT	5T32AI007438-08	41
2000	Failing HAART--Do nutritional &clinical benefits persist	5M01RR000054-39-682	491
2000	SAFETY AND EFFICACY OF RS 79070 ORAL GANCICLOVIR VS IV GANCICLOVIR	5M01RR000054-39-630	491
1999	CORE--IMMUNOVIROLOGY	5P30AI042853-02-9002	905
1999	SAFETY AND EFFICACY OF RS 79070 ORAL GANCICLOVIR VS IV GANCICLOVIR	5M01RR000054-38-630	491
1999	CYTOKINES AND CYTOMEGALOVIRUS IN AIDS RELATED LUNG DISEASE	5M01RR000054-38-657	491
1999	ORALLY ADMINISTERED SP 303 FOR TREATMENT OF DIARRHEA IN AIDS PATIENTS	5M01RR000054-38-656	491
1999	CYTOKINES AND CMV IN AIDS RELATED LUNG DISEASE	5R01HL057875-04	2
1999	NEMCH CLINICAL RESEARCH ON AIDS TRAINING GRANT	5T32AI007438-07	41
1999	HIV PATHOGENESIS TRAINING PROGRAM	5T32AI007389-10	52
1999	SAFETY OF SUBCUTANEOUS RECOMBINANT RH INTERLEUKIN 12 IN HIV INFECTED PATIENTS	5M01RR000054-38-610	491
1999	SAFETY AND EFFICACY OF OXANDROLONE ON BODY WT/COMP IN HIV INFECTED MALE PATIENTS	5M01RR000054-38-625	491
1999	SAFETY, TOL AND ACTIVITY ON PLASMA VIREMIA OF MULTIDOSE SC RHU IL10 IN HIV INFEC	5M01RR000054-38-636	491
1999	SAFETY, TOL &ACTIVITY ON VIREMIA OF MULTIDOSE SC RHU IL10 IN HIV INFECTION	5M01RR000054-38-638	491
1998	CORE--IMMUNOVIROLOGY	1P30AI042853-01-9002	905
1998	SAFETY OF SUBCUTANEOUS RECOMBINANT RH INTERLEUKIN 12 IN HIV INFECTED PATIENTS	3M01RR000054-37-610	491
1998	SAFETY AND EFFICACY OF RS 79070 ORAL GANCICLOVIR VS IV GANCICLOVIR	3M01RR000054-37-630	491
1998	SAFETY AND EFFICACY OF OXANDROLONE ON BODY WT/COMP IN HIV INFECTED MALE PATIENTS	3M01RR000054-37-625	491
1998	SAFETY, TOL AND ACTIVITY ON PLASMA VIREMIA OF MULTIDOSE SC RHU IL10 IN HIV INFEC	3M01RR000054-37-636	491
1998	SAFETY, TOL &ACTIVITY ON VIREMIA OF MULTIDOSE SC RHU IL10 IN HIV INFECTION	3M01RR000054-37-638	491
1998	CYTOKINES AND CMV IN AIDS RELATED LUNG DISEASE	5R01HL057875-03	2
1996	CYTOKINES AND CMV IN AIDS RELATED LUNG DISEASE	1R01HL057875-01	2
1996	RANDOMIZED PARALLEL OPEN LABEL STUDY COMPARING SAQUINARVIR SOFT GEL	5M01RR000054-35-599	491
1995	CYTOKINE BLOCKADE OF HIV-1 REPLICATION	5R01AI033290-03	5
1995	VITAMIN D AND CMV--EFFECTS ON HIV INFECTED MONOCYTES	5K08AI001046-05	7
1994	CYTOKINE BLOCKADE OF HIV-1 REPLICATION	5R01AI033290-02	5
1994	VITAMIN D AND CMV--EFFECTS ON HIV INFECTED MONOCYTES	5K08AI001046-04	7
1993	CYTOKINE BLOCKADE OF HIV-1 REPLICATION	1R01AI033290-01A1	5
1993	VITAMIN D AND CMV--EFFECTS ON HIV INFECTED MONOCYTES	5K08AI001046-03	7
1992	VITAMIN D AND CMV--EFFECTS ON HIV INFECTED MONOCYTES	5K08AI001046-02	7
1986	PATHOGENESIS OF HUMAN CYTOMEGALOVIRUS INFECTION	5F32CA008014-02